Skip to content

EBITDA at other companies

Insight Molecular Diagnostics Inc. Common Stock logo
Insight Molecular Diagnostics Inc. Common StockIMDX
-$3.78M+40.1%
Vor Biopharma logo
Vor BiopharmaVOR
-$35.13M-8.2%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$20.88M-43.7%
CareDx logo
CareDxCDNA
$5.1M+152%
Labcorp Holdings logo
Labcorp HoldingsLH
Quest Diagnostics logo
Quest DiagnosticsDGX

Other financials

Income statement

See full
Revenue$17.3M+11.7%
Gross profit$10.2M+11.9%
Operating income-$3.4M-1.5%
Net income-$4.0M-5.7%
EPS (diluted)-$0.17+15.0%

Balance sheet

See full
Cash & equivalents$21.7M+90.6%
Total debt$27.1M+15.8%
Total equity$14.4M+125%
Total assets$52.0M+28.9%

Cash flow

See full
Operating cash flow-$10.4M+2.4%
CapEx$228.0K+102%
Free cash flow-$10.6M+1.3%

Valuation

See full
Market cap$112.34M-28.2%
Enterprise value$117.78M-22.1%
P/S1.6×-1.0×

Profitability

See full
Gross margin58.3%-1.0pp
Operating margin-20.6%-2.9pp
Net margin-29.5%+2.5pp
FCF margin-27.5%

Returns & leverage

See full
Return on equity-193.6%+355pp
Debt / equity1.9×-1.8×
Current ratio3.5×+1.1×

Where this comes from

Calculated from Exagen Inc.’s reported figures.

$2.9Mebit+
-Depreciation Depletion & Amortization
=-$2.86M

The official record: Exagen Inc.’s 10-K, filed March 16, 2021, on SEC EDGAR. View the filing →

Questions, answered.

What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.